Biocryst Pharmaceuticals buy Cantor Fitzgerald
Start price
29.04.25
/
50%
€7.44
Target price
29.04.26
€17.56
Performance (%)
-12.98%
Price
12.12.25
€6.45
Summary
This prediction is currently active. The prediction for Biocryst Pharmaceuticals disappoints with a performance of -12.98%. This prediction currently runs until 29.04.26. The prediction end date can be changed by Cantor_Fitzgerald at any time. Cantor_Fitzgerald has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Biocryst Pharmaceuticals | -1.073% | -1.073% |
| iShares Core DAX® | 0.734% | -0.964% |
| iShares Nasdaq 100 | -2.686% | -2.409% |
| iShares Nikkei 225® | -2.261% | -4.038% |
| iShares S&P 500 | -1.346% | -1.510% |
Comments by Cantor_Fitzgerald for this prediction
In the thread Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $20.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat
Stopped prediction by Cantor_Fitzgerald for Biocryst Pharmaceuticals
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€5.72
15.10.25
15.10.25
€22.38
15.10.26
15.10.26
12.83%
12.12.25
12.12.25
